A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study

Table 1 Characteristics of all analyzed patients

	C-ion RT (n = 31)	TACE (n = 23)	p-value
Age, year, median (range)	78 (45–95)	76 (59–90)	0.35
Sex (male: female)	15:16	10:13	0.73
AFP, ng/ml, median (range)	11.3 (1.6–28,006)	9.1 (2.0–300.4)	0.23
PS (0:1:2)	18:11:2	12:11:0	0.90
Child-Pugh class (A:B:C)	29:2:0	14:9:0	< 0.01
BCLC classification (A:B:C)	18:0:13	13:0:10	0.91
Tumor size, mm, median (range)	34 (11–78)	27 (8–60)	< 0.05
Etiology, (HCV-Ag:HBs-Ab:NASH/NAFLD:Alcohol)	19:5:6:1	15:1:5:2
Total dose of C-ion RT, (52.8 Gy (RBE)/4 fr: 60 Gy (RBE)/4 fr: 60 Gy (RBE)/12 fr)	16:14:1

Abbreviations: AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, C-ion RT carbon ion radiotherapy, fr fractions, HBs-Ab hepatitis B surface antibody, HCV-Ag hepatitis C antigen, NASH/NAFLD non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, PS performance status, RBE relative biologic effectiveness, TACE transarterial chemoembolization

ISSN: 1748-717X